Drawing for SPIDERWORT

USPTO serial 87615979

SPIDERWORT

Reviewed by CopyMark Law Group

Reg. 5947141Status 705Registered
Filing date
Status date
Registration date
Dec 31, 2019
Examiner
COWARD, JEFFERY
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights. Track next renewal deadlines in TSDR and WIPO records.

Status 705: Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights.

Need help with SPIDERWORT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

R. Scott Keller

R. Scott Keller Warner Norcross + Judd LLP150 Ottawa Avenue NW1500 Warner BuildingGrand Rapids, MI 49503

Goods and services

ClassDescriptionStatusFirst use
001Biomaterial for use in 3D in vitro research and regenerative medicine research; biomaterial for use in 3D in vitro scientific and regenerative medicine research; Cell vector for scientific and research use, namely, a scaffold for transporting or implanting mammalian cells for scientific and research use; Biological consumable, namely, a disposable biomaterial polymer for use in cell culture for scientific research purposesACTIVE—
005Natural biomaterials for augmentation of bone and other tissues for medical and cosmetic purposes; biocompatible biomaterial surgical implants comprised of living tissue; Kits for providing 3D implantable scaffolds for mammalian cell culture research comprised of cellulose scaffolds comprising living tissue, tools to handle and manipulate the scaffold and biocompatible adhesive to immobilize the scaffold; Kits for providing 3D implantable scaffolds comprising living tissue for tissue regeneration in medical and cosmetic applications containing cellulose scaffold, tools to handle and manipulate the scaffold and biocompatible adhesive to immobilize the scaffoldACTIVE—
009[ Biological and wetware platforms, namely, computer software platforms for performing and analyzing biological functions in humans; Computer software for analyzing attributes of biomaterial structure with or without the use of artificial intelligence ]SECTION 8 - CANCELLED—
010Medical devices, namely, biocompatible biomaterial surgical implants comprised of artificial material and surgical instruments; artificial biomaterials for augmentation of bone and other tissues for medical and cosmetic purposes; Kits for providing 3D implantable scaffolds for mammalian cell culture research comprised of cellulose scaffolds comprising artificial materials, tools to handle and manipulate the scaffold and biocompatible adhesive to immobilize the scaffold; Kits for providing 3D implantable scaffolds comprising artificial materials for tissue regeneration in medical and cosmetic applications containing cellulose scaffold, tools to handle and manipulate the scaffold and biocompatible adhesive to immobilize the scaffoldACTIVE—
042Research and development services in the biotechnology field; Tissue Engineering, namely, designing a 3D scaffold to enable cell growth for medical applications; Biodesign, namely, designing a platform for designing custom biocompatible implants for medical and cosmetic purposes; consulting services in the field of biotechnology; bio-engineering; biomimicry; medical and scientific research in the fields of body modification, bio-engineering and biomimicryACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 9, 2026NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Mar 9, 2026C15PREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Mar 9, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 5, 2025E815TEAS SECTION 8 & 15 RECEIVED—
Feb 24, 2025ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Dec 31, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Apr 29, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 29, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 29, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 29, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 29, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Dec 31, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 15, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 15, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 25, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 12, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 12, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Sep 12, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 12, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 12, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 12, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 12, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 12, 2019ALIEASSIGNED TO LIE—
Sep 6, 2019ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Apr 24, 2019GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Apr 24, 2019GNSIINQUIRY TO SUSPENSION E-MAILED—
Apr 24, 2019CNSISUSPENSION INQUIRY WRITTEN—
Oct 3, 2018GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Oct 3, 2018GNSLLETTER OF SUSPENSION E-MAILED—
Oct 3, 2018CNSLSUSPENSION LETTER WRITTEN—
Jun 30, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 29, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 29, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 11, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 11, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 11, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 26, 2017DOCKASSIGNED TO EXAMINER—
Sep 27, 2017MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Sep 26, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—

Frequently asked questions

Related guidance